The Role of Biologic Therapies in Dermatology.
نویسندگان
چکیده
Biologic therapy has dramatically changed the way medicine, and specifically dermatology, is practiced today. The use of biologic agents in dermatology is evolving, with psoriasis being the most common indication for which biologics are used currently. However, several other dermatologic diseases seem to be responsive to biologic therapy, and continuing research and development efforts are elucidating the benefit-risk profiles of various biologic medications in these dermatologic conditions. Although biologic agents have revolutionized the management of dermatologic conditions, cost must also be considered when evaluating management options, especially compared with traditional agents. For example, the cost of 1 year of induction and maintenance treatment of psoriasis in 2014 was estimated to be $53,909 for ustekinumab, $46,395 for etanercept, and $39,041 for adalimumab. Nonetheless, because of their efficacy, the cost of a biologic may be offset by significant reductions in the number of hospital stays, reduction in use of other systemic therapies, and increased satisfaction by patients.32 Thus, understanding their mechanisms of action, labeled and off-label uses in dermatology, and common adverse effects helps to inform clinical decision making and improve patient outcomes.
منابع مشابه
Preoperative Evaluation and Management of Patients Receiving Biologic Therapies
The preoperative care of patients undergoing orthopedic surgery and treated with biologic agents is of great significance.Perioperative use of biologic agents could lead to such complications as infection and delayed postoperative woundhealing. This narrative review aimed to evaluate the current information on the use of biologic agents in patientsundergoing orthopedic surgery...
متن کاملOVELTIES IN DERMATOLOGY nterferon Assays in the Diagnosis of Tuberculosis Infection in soriasis Patients Who Are Candidates for Biologic Therapies
متن کامل
CONTROVERSIES IN DERMATOLOGY Biologic Therapies for Moderate to Severe Psoriasis Are Not Interchangeable
متن کامل
Optimizing topical therapies for treating psoriasis: a consensus conference.
In 2010, an expert committee of physicians and researchers in the field of dermatology working together as the Psoriasis Process of Care Consensus Panel developed consensus guidelines for the treatment of psoriasis. As much as possible, the guidelines were evidence based but also included the extensive clinical experience of the dermatologists. Psoriasis is a lifelong disease that requires long...
متن کاملRecapturing adequate control of psoriasis by additional immunosuppressive agents alongside ustekinumab
ADA: antidrug antibodies DLQI: Dermatology Life Quality Index PASI: Psoriasis Area and Severity Index INTRODUCTION Etanercept, adalimumab, infliximab, and ustekinumab are all biologic therapies licensed for the treatment of chronic plaque psoriasis in the United Kingdom. Although these therapies have advanced the treatment of psoriasis, they can lose effectiveness with time. Three studies looke...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- The Medical clinics of North America
دوره 99 6 شماره
صفحات -
تاریخ انتشار 2015